Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
cerdulatinib janus kinase 1 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.71 phase 2 inhibitor
cerdulatinib janus kinase 1 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.71 phase 2 unknown
cerdulatinib janus kinase 2 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.19 phase 2 unknown
cerdulatinib janus kinase 2 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.19 phase 2 inhibitor
cerdulatinib janus kinase 3 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.41 phase 2 unknown
cerdulatinib janus kinase 3 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.41 phase 2 inhibitor
cerdulatinib tyrosine-protein kinase syk NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.71 phase 2 unknown
cerdulatinib tyrosine-protein kinase syk NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Lymphoma
Non-Hodgkin[MeSHID:D008228]
Eczema[MeSHID:D004485]
Dermatitis
Atopic[MeSHID:D003876]
B-Cell Lymphomas[MeSHID:D016393]
Vitiligo[MeSHID:D014820]		 0.71 phase 2 inhibitor
click here to return to the previous page